Skip to main content
. 2021 Jan 13;29(1):52–60. doi: 10.5606/tgkdc.dergisi.2021.19586

Table 3. Demographic and clinical data of GMTs in our cohort and cases retrieved from NCBI database.

  Our cohort p* NCBI database p*
Total
(n=31)		 Benign
(n=14)		 Malignancy (n=17) Total
(n=47)		 Benign
(n=24)		 Malignancy
(n=23)
n Mean±SD n Mean±SD n Mean±SD n Mean±SD n Mean±SD n Mean±SD
Age (year)   27.8±8.2   31.1±8.6   24.2±6.4 0.019   45.4±16.7   42.3±15.4   48.4± 17.7 0.22
Sex             0.37             0.34
Male 26   12   14     26   13   13    
Female 5   2   3     21   11   10    
Maximum diameter (cm)   18.1±5.1   16.4±4.7   19.5±5.0 0.039   20.8±8.1   19.8±7.5   21.7±8.6 0.44
Adjuvant therapy                            
Chemotherapy 10   -   10 -   5   -   5    
Radiotherapy -   -   -     4   -   4    
Chemoradiotherapy -   -   -     1   -   1    
Prognosis             -             -
Relapse 3   -   3     1   -   1    
Metastasis 1   -   1     -   -   -    
DFS (year) -   -     2.3±0.9   -   -     1.9±1.7  
OS (year) -   -     2.6±0.9   -   -     1.8±1.4  
Complication             -             -
Arrhythmias 2   1   1     -   -   -    
Cholera 1   -   1                  
Vocal cord paralysis -   -   -     1   1   -    
Hemi thorax -   -   -     1   -   1    
Flaccid paralysis -   -   -     1   -   1    
GMTs: Giant mediastinal tumors; NCBI: National Center for Biotechnology Information; SD: Standard deviation; DFS: Disease-free survival; OS: Overall survival; * Benign vs. malignant tumors; * p<0.05.